ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022
Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Global Performance of Human Papillomavirus Typing, Screening, and Evaluation As Assessed Using Proficiency Panels Traceable to International Standards: A Retrospective Analysis, 2008-2024.Journal of medical virology · 2026Article
- Comparative Evaluation of HPV PLUS ELITe MGB® and Allplex™ HPV HR Assays for High-Risk Human Papillomavirus Genotyping in Cervical Samples.Journal of medical virology · 2026Article
- International Collaborative Study on Human Papillomavirus Analytical Thresholds for Sensitivity and Specificity in Cervical Screening.Journal of medical virology · 2026Article
- Human Papillomavirus Primary Screening and Collaboration in Quality Assurance Work between Laboratories.Acta cytologica · 2026Review
- Nanopore sequencing of non-oncogenic oral Papillomaviruses from people living with HIV.Research square · 2025Article
- Global burden and future trends of head and neck cancer: a deep learning-based analysis (1980-2030).PloS one · 2025Article
- Validity of MehrviruBMC infectious diseases · 2024Article
- Telomere Length, Telomerase Activity, and Vaginal Microbiome in Patients with HPV-Related Precancerous Lesions.International journal of molecular sciences · 2024Article
- Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.Nature communications · 2024Article
- Global burden of head and neck cancers from 1990 to 2019.iScience · 2024Article
- A human papillomavirus whole genome plasmid repository: A resource for HPV DNA quality control reagents.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2023Article
- Assessing artificial intelligence enabled liquid-based cytology for triaging HPV-positive women: a population-based cross-sectional study.Acta obstetricia et gynecologica Scandinavica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProficient Human Papillomavirus (HPV) genotyping services are essential to support HPV and cervical cancer elimination strategies, in particular to support HPV vaccine research.
objectivesTo perform a global HPV genotyping proficiency study, with evaluation in relation to previous proficiency studies. STUDY
designThe proficiency panel contained 44 coded samples (40 samples containing one or more purified HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/68a/68b) in human DNA, 1 human DNA control and 3 DNA extraction controls). Proficiency required detection of both single and multiple infections of 50 International Units of HPV 16/18, of 500 genome equivalents for other HPV types and no false positivity.
resultsOne hundred and thirty-two laboratories submitted 211 datasets. Most assays used (182/211 datasets) were commercially available. An all-time high of 75% of the datasets were 100% proficient. One or more false positives were found in 17.5% of datasets. Among laboratories who participated in the 2019 proficiency study, full proficiency increased from 25% in 2019 to 60% in 2021. The high overall proficiency was mostly attributable to a large number of new laboratories, which used similar assays.
conclusionsThe worldwide deterioration in comparability and reliability of HPV testing found in 2019 is now reversed and an overall increase in proficiency is found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.